- Home
- SEVN vs MSLE Comparison
SEVN vs MSLE Comparison
Compare SEVN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEVN | MSLE |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 154.6M |
| IPO Year | 2008 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SEVN | MSLE |
|---|---|---|
| Price | $7.51 | $9.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 121.1K | 17.2K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $39.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $5.44 |
| 52 Week High | $11.15 | $13.39 |
Technical Indicators
Market Signals| Indicator | SEVN | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 45.66 |
| Support Level | $7.41 | $6.71 |
| Resistance Level | $7.84 | $10.46 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 16.48 | 21.67 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.